Page 8 - ஆஸ்திரேலிய காப்புரிமை அலுவலகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BRPTO anticipates Phase II of Patent Prosecution Highway Programme

On 1 January 2021 Ordinance 404 came into force, establishing Phase II of the Patent Prosecution Highway (PPH) Programme in Brazil. Phase II was published by the Brazilian Patent and Trademark Office (BRPTO) in the last week of 2020 and modifies the limits and requirements for requesting participation in the PPH Programme, which are detailed below. With this new phase of the PPH Programme, the previous Resolution 252 (establishing Phase I) has been revoked. PPH Programme The PPH Programme allows the examination of a patent application to be expedited in Brazil whenever a corresponding patent has been granted in one of the countries participating in the programme, upon the applicant s request.

United statesUnited kingdomInternational patent classificationEuropean patent officeProperty office of singaporeSwedish intellectual property officeUnited kingdom intellectual property officeChina national intellectual property administrationTrademark officeKorean intellectual property officeJapan patent officeAustrian patent officePatent prosecution highwayBrazilian patentUnited states patentEuropean patent

KMU können sich neue Logos und Designs fördern lassen

KMU können sich neue Logos und Designs fördern lassen
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Austrian patent officeTake meaninglessAustrian patent office thursdayProperty rightsFree securities tradingஆஸ்திரேலிய காப்புரிமை அலுவலகம்ப்ராபர்டீ உரிமைகள்

Propanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent Office

Propanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent Office MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the first granted patent for an important patent family (i.e., a set of patents filed in various countries to protect an invention) was received by the Company from the Australian Patent Office. The granted patent protects proprietary claims, capturing methods and uses for pancreatic proenzymes to treat cancer, specifically, by targeting and eradicating cancer stem cells (“CSCs”). CSCs represent only a small fraction of the cancer cells within a tumor and can remain dormant for extended periods of time, thereby evading standard treatments like chemotherapy and radiotherapy that target dividing cells. Conseque

James nathanielszJulian kenyonExchange commissionAustralian patent officePropanc biopharma incCompany registration statement on formCompany mechanism of actionPropanc biopharmaAustralian patentChief executiveChief scientificRegistration statementஜூலியன் கெந்யந்பரிமாற்றம் தரகுஆஸ்திரேலிய காப்புரிமை அலுவலகம்நிறுவனம் பதிவு அறிக்கை ஆன் வடிவம்